Fig. 6: Antiglycation and anti-inflammatory effects of 18β-glycyrrhetic acid.

A GO-affinity assay; (B) GO-AGEs breaker assay; (C) GO-AGEs formation assay; (D) Cell viability in GO-AGEs/UVB-treated HaCaT human keratinocytes; (E–H) Levels of proinflammatory markers including (E) IL-1β, (F) IL-6, (G) TNF-α, and (H) PGE2 in GO-AGEs/UVB-treated HaCaT cells. ###p < 0.001 vs. Control (untreated) group; *p < 0.05, **p < 0.01, and ***p < 0.001 vs. GO, GO-AGE-, or GO-AGEs/UVB-treated group. Results are expressed as the mean ± SEM (n = 3).